Regenxbio Inc

NASDAQ:RGNX   3:59:53 PM EDT
29.04
+0.18 (+0.62%)
Products, Regulatory

Regenxbio Announces Continued Progress, Expansion Of Clinical Development Program For Rgx-121 For Treatment Of Mucopolysaccharidosis Type II

Published: 09/30/2020 11:40 GMT
Regenxbio Inc (RGNX) - Regenxbio Announces Continued Progress and Expansion of Clinical Development Program for Rgx-121 for Treatment of Mucopolysaccharidosis Type Ii (mps Ii).
Regenxbio Inc - New Ind for Phase I/ii Trial Cleared by FDA to Evaluate Rgx-121.
Regenxbio Inc - New Ind for Phase I/ii Trial Cleared by FDA to Evaluate Rgx-121 Expected to Initiate in 2h 2020.